Back to search

University of Leeds

Modelling plasma cell differentiation to risk stratify secondary antibody deficiencies for immunoglobulin replacement therapy

Abstract

dc:description.abstract

B-cells of patients with secondary and primary antibody deficiency often exhibit defects in maturation, activation, or survival, which may lead to impaired immune responses after SARS-CoV-2 vaccination. These defects contribute to vaccine non- responsiveness in some patients. The underlying mechanisms and the feasibility of pre-vaccination risk stratification remain unclear. To investigate B-cell intrinsic differentiation capacities in a heterogeneous cohort of vaccine-responding and non- responding antibody-deficient patients, an in vitro plasma cell differentiation model has been utilised. Such an approach may also be useful in assessing their suitability for immunoglobulin replacement therapy (IgRT). B-cells from participants enrolled in the COV-AD study, taken after their fourth SARS-CoV-2 vaccine dose, were isolated and induced to differentiate into plasma cells. B-cell functionality at critical differentiation stages was assessed using flow cytometry, ELISA, BCR analysis, and RNA sequencing. The study revealed distinct differences in B-cell differentiation between vaccine responders and non-responders. Non-responders (n=15) and a subset of responders (n=10/35) exhibited significantly reduced or absent expression of the BAFF-R survival receptor. Immunoglobulin heavy chain sequencing showed no significant differences in BCR profiles between responders and non-responders. Both patient groups displayed reduced intracellular and secreted IgG and IgA expression compared to healthy controls. Atypical B-cell differentiation profiles in antibody deficient patients, particularly reduced BAFF-R expression, may underpin impaired SARS-CoV-2 vaccine responses. The identification of BAFF-R as a critical survival receptor emphasises its potential as a biomarker for risk stratification. Integrating BAFF-R profiling into clinical workflows could help identify patients at risk of poor immune outcomes, enabling tailored therapeutic interventions. Refining this in vitro plasma cell differentiation model to allow for faster assessments, focusing on BAFF-R levels and other key markers, will enhance its feasibility as a practical tool for pre-IgRT risk stratification in clinical settings.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Leeds
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • O'Callaghan, Eleanor Rose
Advisors dc:contributor.advisor
  • Savic, Sinisa
  • Doody, Gina

Rights

Language dc:language.dcterms_iso639_2
eng

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

O'Callaghan, Eleanor Rose. Modelling plasma cell differentiation to risk stratify secondary antibody deficiencies for immunoglobulin replacement therapy. doctoral thesis, University of Leeds, 2025.